Clinical trial
Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate
NCT00319228 · Grifols Biologicals, LLC, Industry · Active, not recruiting
Key facts
| NCT number | NCT00319228 |
|---|---|
| Title | Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate |
| Official title | A Phase II/III Pivotal Trial Evaluating the Safety, Pharmacokinetic Properties and Efficacy of a Plasma-Derived Anti-thrombin III Concentrate With Administration in Surgery, Pregnancy and Thromboembolic or Thrombotic Events |
| Lead sponsor | Grifols Biologicals, LLC, Industry |
| Status | Active, not recruiting |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Antithrombin III Deficiency |
| Intervention type | Drug |
| Interventions | Plasma-derived AT-III concentrate |
| Enrollment | 30 |
| Start date | Jan 1, 2006 |
| Primary completion | Dec 1, 2028 |
| Completion | Mar 1, 2029 |
| First posted | Apr 27, 2006 |
| Last update posted | Aug 25, 2023 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: